Clinical Trials Logo
  1. Home
  2. Other
  3. NCT00713674
  4. Details
NCT00713674 Clinical Trial

Comparison of Decolonization of Methicillin-resistant Staphylococcus Aureus (MRSA) Using Theraworx

Methicillin-Resistant Staphylococcus Aureus Clinical Trial

— SJMRSA  

Official title:
Comparison of Decolonization of MRSA Using Theraworx

Clinical Trial Details — Status: Withdrawn

Administrative data
NCT number NCT00713674
Other study ID # SJMRSA-01
Secondary ID
Status Withdrawn
Phase N/A
First received July 7, 2008
Last updated March 21, 2017
Start date March 2008
Est. completion date February 2009

Study information
Verified date March 2017
Source Mercy Research
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to examine treatment method of Methicillin-resistant Staphylococcus aureus (MRSA) decolonization in patients.

Description:

Decolonization therapy is indicated for management of patients with MRSA. Theraworx is reported to be an effective antimicrobial against multiple organisms. In this study, patients with positive MRSA colonization culture will be treated with Theraworx to evaluate decolonization duration capability.

Recruitment information / eligibility
Status Withdrawn
Enrollment 0
Est. completion date February 2009
Est. primary completion date February 2009
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Positive MRSA culture

Exclusion Criteria:

- Patients currently on or start antibiotic therapy directed for MRSA.(Prophylaxis antibiotic for surgical procedure not considered therapy.)

- Patients with MRSA infected wounds

- Patients under the age of 18 years

- A woman currently pregnant or nursing a child

- Patients participating in another study within 30 days of randomization

Study Design

Related Conditions & MeSH terms

Intervention

Other:
• Theraworx
Theraworx swab intranasal BID for 5 days
Drug:
• mupirocin antibiotic ointment
mupirocin antibiotic ointment swab intranasal BID for 5 days

Locations
Country Name City State
n/a

Sponsors (1)
Lead Sponsor Collaborator
Mercy Research

Outcome
Type Measure Description Time frame Safety issue
Primary Evidence of decolonization confirmed by intranasal culture Up to 14 days post treatment (+/- 1-2 days)
Secondary Economic-Cost comparison of treatment Evidence of decolonization 5 days of treatment
See also
  Status Clinical Trial Phase
Completed NCT05529173 - Povidone-Iodine for Nasal Decolonization Phase 4
Completed NCT00980980 - Cluster Randomized Trial of Hospitals to Assess Impact of Targeted Versus Universal Strategies to Reduce Methicillin-resistant Staphylococcus Aureus (MRSA) in Intensive Care Units (ICUs) N/A
Recruiting NCT03412500 - Vancomycin Dosage Adjustment for MRSA Infections Phase 4
Recruiting NCT02566928 - Patient-Centered Comparative Effectiveness Research (CER) Study of Home-based Interventions to Prevent CA-MRSA Infection Recurrence Phase 4
Terminated NCT01196169 - Daptomycin Use for Antimicrobial Prophylaxis in Methicillin Resistant Staphylococcus Aureus (MRSA) Colonized Adult Patients Undergoing Primary Elective Hip, Knee, or Shoulder Arthroplasty Phase 4
Completed NCT00996112 - Primary Care Management of Community-Acquired, Methicillin-Resistant Staphylococcus Aureus (CA-MRSA) Infections N/A
Not yet recruiting NCT00773799 - Mastering Hospital Antimicrobial Resistance and Its Spread Into the Community N/A
Not yet recruiting NCT00773864 - Mastering Hospital Antimicrobial Resistance and Its Spread Into the Community-Healthcare Workers N/A
Completed NCT01350479 - Gown and Glove Use to Prevent the Spread of Infection in VA Community Living Centers N/A
Recruiting NCT03637400 - Short and Long Term Outcomes of Doxycycline Versus Trimethoprim-Sulfamethoxazole for Skin and Soft Tissue Infections Treatment Phase 2
Completed NCT01200654 - Population Pharmacokinetics of Linezolid Phase 4
Withdrawn NCT00856089 - Efficacy Study of Altabax to Clear Methicillin-resistant Staphylococcus Aureus (MRSA) Nasal Colonization Phase 4
Recruiting NCT04171817 - Animal-Assisted Visitation Program Chlorhexidine Trial Phase 4
Completed NCT00324922 - Vancomycin Or Trimethoprim/Sulfamethoxazole for Methicillin-resistant Staphylococcus Aureus Osteomyelitis Phase 3
Completed NCT02814916 - Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA Phase 3
Not yet recruiting NCT05632315 - PMT for MDRO Decolonization Phase 2
Not yet recruiting NCT01356472 - Linezolid Alone or Combined With Carbapenem Against Methicillin-resistant Staphylococcus Aureus (MRSA) in Ventilator-associated Pneumonia Phase 4
Completed NCT03886623 - A Systematic Oral Care Program in Post-Mechanically Ventilated, Post-Intensive Care Patients N/A
Completed NCT01141101 - Risk Factors for Early Infant Colonization With Methicillin-Resistant Staphylococcus Aureus N/A
Completed NCT01138462 - Control of MRSA in Nursing Homes: Decolonization vs Standard Precautions N/A